Skip to main content
. 2019 Nov 26;2019(11):CD009286. doi: 10.1002/14651858.CD009286.pub3

Li 2006.

Methods Parallel group
Participants All pathological types of stroke, CT or MRI needed for diagnosis
Inclusion criteria: depression diagnosed by Chinese Classification of Mental Disorders 3 and HAMD ≥ 18, no previous organic brain disorder, and no previous psychiatric history, clear consciousness, no comprehension problems, normal language, first acute stroke, first episode of depression
Treatment: 52 people, mean ± SD age 61.12 ± 10.25, 32 men
Control: 53 people, mean ± SD age 60.89 ± 9.12, 35 men
Interventions Treatment: citalopram 20 mg daily plus usual care
Control: usual care
Duration of treatment: 12 weeks
Duration of follow‐up (end of treatment to end of study): 0
Outcomes HDRS (also known as HAMD)
BI
CSS
MMSE
Side effects reported according to the participant's complaints and observation, no description of who recorded AEs; and reported only for the treatment group
Funding source Source of funding not stated
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk No description
Allocation concealment (selection bias) Unclear risk No description
Blinding of participants and personnel (performance bias) 
 All outcomes High risk No placebo
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk No description
Incomplete outcome data (attrition bias) 
 All outcomes High risk 2 dropouts in treatment group, 4 in control group. 1 in treatment group died, and 2 in the control group died (i.e. > 5%)
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Unclear risk Baseline balanced